Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ESBATech has announced that the company has successfully completed its Phase I clinical study of the company's lead product candidate, ESBA105, in ophthalmic indications.
Subscribe to our email newsletter
In April 2008, ESBATech initiated the Phase I study designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers.
This trial was conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications. Several additional clinical studies are in the preparation stages.
Dominik Escher, CEO of ESBATech, said: “The completion of this Phase I study with ESBA105 in ophthalmic indications marks a critical clinical milestone for the company. Recently, ESBATech secured CHF23 million in an extended Series B venture financing round.
“This financing will fund further clinical studies with ESBA105 in ophthalmic indications, as well as build broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and other antibody fragments. We look forward to announcing the results of this Phase I study and future clinical trials.”